ApoE-Ph nanoagents have a higher PTT efficiency for glioblastoma (GBM) by keeping the balance of radiation-modulated NIR-fluorescence imaging at 1,550 nm and non-radiation NIR-PTT, opening a novel window for boosting theranostics in other cancers (Wang et al., 2022a). This evidence concerns the gene APOE and glioblastoma.